A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Conditions: Extensive Stage-small Cell Lung Cancer Interventions: Drug: Ifinatamab deruxtecan; Drug: Atezolizumab; Drug: Carboplatin; Drug: Etoposide Sponsors: Daiichi Sankyo; Merck Sharp& Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials